{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T16:40:38Z","timestamp":1736354438866,"version":"3.32.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011852","name":"Paracelsus Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011852","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Die Autoimmun-Innenohrerkrankung (\u201eautoimmune inner ear disease\u201c, AIED) imponiert durch rezidivierende, fluktuierende sensorineurale Schwerh\u00f6rigkeit mit assoziierten vestibul\u00e4ren Symptomen. Therapeutisch kommen Kortikosteroide und Immunsuppressiva zum Einsatz. Trotz Behandlung kann es zu progressiver Schwerh\u00f6rigkeit bis hin zur Ertaubung kommen, sodass ein Cochleaimplantat (CI) indiziert ist. Hier wird der Fall eines 25-j\u00e4hrigen Patienten pr\u00e4sentiert, bei dem es im Rahmen der CI-Versorgung zu Impedanzschwankungen kam, welche in Abh\u00e4ngigkeit von der vorab begonnenen Therapie mit dem Tumornekrosefaktor(TNF)-\u03b1-Inhibitor Adalimumab standen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Zielsetzung<\/jats:title>\n                <jats:p>Hat eine immunmodulatorische Therapie bei AIED-Patienten nach CI-Versorgung einen Einfluss auf die Versorgungsqualit\u00e4t?<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Die Autoren dokumentierten \u00fcber ein Jahr hinweg die Impedanzen und die Ergebnisse des Freiburger Sprachtests ihres Patienten in Abh\u00e4ngigkeit von der Adalimumab-Therapie.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Unmittelbar nach Implantation zeigten sich unauff\u00e4llige Impedanzwerte. Im weiteren Verlauf nahmen diese jedoch zu, weshalb rezidivierend Anpassungen der CI-Funktion n\u00f6tig waren. Nach Wiederbeginn der Therapie mit Adalimumab sanken die Impedanzen wieder ab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerung<\/jats:title>\n                <jats:p>Eine CI-Versorgung kann bei AIED-Patienten eine suffiziente H\u00f6rrehabilitation erm\u00f6glichen. Je nach Aktivit\u00e4t der Grunderkrankung kann es jedoch zu schwankenden Impedanzen kommen. Eine immunmodulatorische Therapie kann somit durchaus sinnvoll und n\u00f6tig sein, um eine ad\u00e4quate H\u00f6rrehabilitation mit dem CI zu erm\u00f6glichen.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00106-024-01472-5","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T15:01:51Z","timestamp":1713798111000},"page":"29-34","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cochleaimplantatversorgung bei Autoimmunschwerh\u00f6rigkeit","Cochlear implantation in patients with autoimmune hearing loss"],"prefix":"10.1007","volume":"73","author":[{"given":"Maximilian","family":"Armstorfer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lennart","family":"Weitgasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Tschani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"R\u00f6sch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"1472_CR1","doi-asserted-by":"crossref","unstructured":"McCabe BF. Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol. 1979 Sep-Oct;88(5 Pt 1):585\u20139.","DOI":"10.1177\/000348947908800501"},{"issue":"5","key":"1472_CR2","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/lio2.28","volume":"1","author":"A Vambutas","year":"2016","unstructured":"Vambutas\u00a0A, Pathak\u00a0SAAO (2016) Autoimmune and Autoinflammatory (Disease) in Otology: What is New in Immune-Mediated Hearing Loss. Laryngoscope Investig Otolaryngol 1(5):110\u2013115 (Oct)","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"6","key":"1472_CR3","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/lio2.508","volume":"28;5","author":"NK Breslin","year":"2020","unstructured":"Breslin\u00a0NK et\u00a0al (2020) Autoimmune inner ear disease: A\u00a0systematic review of management. Laryngoscope Investig Otolaryngol 28;5(6):1217\u20131226 (Nov)","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"4","key":"1472_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000351289","volume":"18","author":"AJ Matsuoka","year":"2013","unstructured":"Matsuoka\u00a0AJ, Harris\u00a0JP (2013) Autoimmune inner ear disease: a\u00a0retrospective review of forty-seven patients. Audiol Neurootol 18(4):228\u2013239","journal-title":"Audiol Neurootol"},{"issue":"5","key":"1472_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/00129492-200109000-00010","volume":"22","author":"MU Rahman","year":"2001","unstructured":"Rahman\u00a0MU et\u00a0al (2001) Etanercept therapy for immune-mediated cochleovestibular disorders: preliminary results in a\u00a0pilot study. Otol Neurotol 22(5):619\u2013624 (Sep)","journal-title":"Otol Neurotol"},{"issue":"4","key":"1472_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000320606","volume":"16","author":"S Cohen","year":"2011","unstructured":"Cohen\u00a0S et\u00a0al (2011) A\u00a0pilot study of rituximab in immune-mediated inner ear disease. Audiol Neurootol 16(4):214\u2013221","journal-title":"Audiol Neurootol"},{"issue":"9","key":"1472_CR7","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1172\/JCI76503","volume":"124","author":"A Vambutas","year":"2014","unstructured":"Vambutas\u00a0A et\u00a0al (2014) Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease. J\u00a0Clin Invest 124(9):4115\u20134122 (Sep)","journal-title":"J Clin Invest"},{"issue":"8","key":"1472_CR8","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1097\/MAO.0b013e3181f0c699","volume":"31","author":"S Aftab","year":"2010","unstructured":"Aftab\u00a0S et\u00a0al (2010) Cochlear implantation outcomes in patients with autoimmune and immune-mediated inner ear disease. Otol Neurotol 31(8):1337\u20131342 (Oct)","journal-title":"Otol Neurotol"},{"issue":"1","key":"1472_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/23772484.2023.2176309","volume":"8","author":"L Weitgasser","year":"2023","unstructured":"Weitgasser\u00a0L et\u00a0al (2023) Autoimmune inner ear disease in a\u00a0young patient\u2014an unsolvable challenge? Acta Oto-laryngologica Case Reports 8(1):29\u201334","journal-title":"Acta Oto-laryngologica Case Reports"},{"issue":"2","key":"1472_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/14670100.2021.1992149","volume":"23","author":"F Atturo","year":"2022","unstructured":"Atturo\u00a0F et\u00a0al (2022) Cochlear implant in immune mediated inner ear diseases: Impedance variations and clinical outcomes. Cochlear Implants Int 23(2):70\u201379 (Mar)","journal-title":"Cochlear Implants Int"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-024-01472-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-024-01472-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-024-01472-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T16:02:41Z","timestamp":1736352161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-024-01472-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1472"],"URL":"https:\/\/doi.org\/10.1007\/s00106-024-01472-5","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"type":"print","value":"0017-6192"},{"type":"electronic","value":"1433-0458"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"assertion":[{"value":"5 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Armstorfer, L.\u00a0Weitgasser, S.\u00a0Tschani und S.\u00a0R\u00f6sch geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}